BUZZ-Street View: Promising new frontiers ahead for Bristol Myers

Reuters

Apr 25, 2025

BUZZ-Street View: Promising new frontiers ahead for Bristol Myers

** Bristol Myers Squibb BMY.N reported higher-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's immune system to fight cancer.

** Median PT of 28 brokerages covering the stock is $56 - data compiled by LSEG

LEGACY STRENGTH VS FUTURE PIPELINE BETS

** Bernstein ("market perform", PT: $62) says "while we like Bristol's beat & raise, the reliance on legacy products & FX makes us more nervous, especially with the ongoing policy & FX volatility"** The brokerage, however, likes the early launch signs for Cobenfy (for schizophrenia treatment) and Opdivo Qvantig which is its newly launched cancer immunotherapy

** Citigroup ("neutral", PT: $51) says with solid results from its legacy portfolio and strong momentum in its growth segment, it expects sustained commercial execution and strategic business development to offset the impact of upcoming patent expirations

** Truist Securities ("buy", PT: $65) says "with its cost-cutting measures, global mfg presence, and continued appetite for BD, we believe BMY is well-positioned to navigate this challenging period with its eyes on a return to growth strategy"

** Leerink Partners ("outperform", PT: $55) says does not anticipate imminent positive catalysts, but notes pipeline optionality over the next few years

(Reporting by Joel Jose in Bengaluru)

((joeljose@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2530139119"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530139119\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2530139119?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-25 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530139119","market":"us","top_or_hot":-1,"title":"BUZZ-Street View: Promising new frontiers ahead for Bristol Myers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: Promising new frontiers ahead for Bristol Myers</title></head><body><p>** Bristol Myers Squibb <span>BMY.N</span> reported <span>higher-than-expected</span> first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's immune system to fight cancer.</p><p>** Median PT of 28 brokerages covering the stock is $56 - data compiled by LSEG</p><p>LEGACY STRENGTH VS <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> PIPELINE BETS</p><p>** Bernstein (\"market perform\", PT: $62) says \"while we like Bristol's beat &amp; raise, the reliance on legacy products &amp; FX makes us more nervous, especially with the ongoing policy &amp; FX volatility\"** The brokerage, however, likes the early launch signs for Cobenfy (for schizophrenia treatment) and Opdivo Qvantig which is its newly launched cancer immunotherapy</p><p>** Citigroup (\"neutral\", PT: $51) says with solid results from its legacy portfolio and strong momentum in its growth segment, it expects sustained commercial execution and strategic business development to offset the impact of upcoming patent expirations</p><p>** Truist Securities (\"buy\", PT: $65) says \"with its cost-cutting measures, global mfg presence, and continued appetite for BD, we believe BMY is well-positioned to navigate this challenging period with its eyes on a return to growth strategy\"</p><p>** Leerink Partners (\"outperform\", PT: $55) says does not anticipate imminent positive catalysts, but notes pipeline optionality over the next few years</p><p> (Reporting by Joel Jose in Bengaluru)</p><p> ((joeljose@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Street View: Promising new frontiers ahead for Bristol Myers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Street View: Promising new frontiers ahead for Bristol Myers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-25 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Street View: Promising new frontiers ahead for Bristol Myers</title></head><body><p>** Bristol Myers Squibb <span>BMY.N</span> reported <span>higher-than-expected</span> first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's immune system to fight cancer.</p><p>** Median PT of 28 brokerages covering the stock is $56 - data compiled by LSEG</p><p>LEGACY STRENGTH VS <a href=\"https://laohu8.com/S/FUTR.UK\">FUTURE</a> PIPELINE BETS</p><p>** Bernstein (\"market perform\", PT: $62) says \"while we like Bristol's beat &amp; raise, the reliance on legacy products &amp; FX makes us more nervous, especially with the ongoing policy &amp; FX volatility\"** The brokerage, however, likes the early launch signs for Cobenfy (for schizophrenia treatment) and Opdivo Qvantig which is its newly launched cancer immunotherapy</p><p>** Citigroup (\"neutral\", PT: $51) says with solid results from its legacy portfolio and strong momentum in its growth segment, it expects sustained commercial execution and strategic business development to offset the impact of upcoming patent expirations</p><p>** Truist Securities (\"buy\", PT: $65) says \"with its cost-cutting measures, global mfg presence, and continued appetite for BD, we believe BMY is well-positioned to navigate this challenging period with its eyes on a return to growth strategy\"</p><p>** Leerink Partners (\"outperform\", PT: $55) says does not anticipate imminent positive catalysts, but notes pipeline optionality over the next few years</p><p> (Reporting by Joel Jose in Bengaluru)</p><p> ((joeljose@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2360032135.SGD","symbol_name":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250425:nL4N3R31B8:1","article_id":"2530139119","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530139119","pubTimestamp":1745588560,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Street View: Promising new frontiers ahead for Bristol Myers** Bristol Myers Squibb BMY.N reported higher-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's immune system to fight cancer.** Median PT of 28 brokerages covering the stock is $56 - data compiled by LSEGLEGACY STRENGTH VS FUTURE PIPELINE BETS** Bernstein  says \"while we like Bristol's beat & raise, the reliance on legacy products & FX makes us more nervous, especially with the ongoing policy & FX volatility\"** The brokerage, however, likes the early launch signs for Cobenfy  and Opdivo Qvantig which is its newly launched cancer immunotherapy** Citigroup  says with solid results from its legacy portfolio and strong momentum in its growth segment, it expects sustained commercial execution and strategic business development to offset the impact of upcoming patent expirations** Truist Securities  says \"with its cost-cutting measu","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","BK4585":"ETF&股票定投概念","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4534":"瑞士信贷持仓","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4559":"巴菲特持仓","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4588":"碎股","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU1670710588.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1670710661.SGD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (SGD) INC","BK4007":"制药","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","BMY":"施贵宝","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1670711123.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) INC","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1323610961.USD":"UBS (LUX) EQUITY SICAV - LONG TERM THEMES (USD) \"P\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC"},"translate_title":"BUZZ街景：百时美施贵宝未来充满希望的新领域","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMY":0.9},"content_text":"BUZZ-Street View: Promising new frontiers ahead for Bristol Myers** Bristol Myers Squibb BMY.N reported higher-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's immune system to fight cancer.** Median PT of 28 brokerages covering the stock is $56 - data compiled by LSEGLEGACY STRENGTH VS FUTURE PIPELINE BETS** Bernstein (\"market perform\", PT: $62) says \"while we like Bristol's beat & raise, the reliance on legacy products & FX makes us more nervous, especially with the ongoing policy & FX volatility\"** The brokerage, however, likes the early launch signs for Cobenfy (for schizophrenia treatment) and Opdivo Qvantig which is its newly launched cancer immunotherapy** Citigroup (\"neutral\", PT: $51) says with solid results from its legacy portfolio and strong momentum in its growth segment, it expects sustained commercial execution and strategic business development to offset the impact of upcoming patent expirations** Truist Securities (\"buy\", PT: $65) says \"with its cost-cutting measures, global mfg presence, and continued appetite for BD, we believe BMY is well-positioned to navigate this challenging period with its eyes on a return to growth strategy\"** Leerink Partners (\"outperform\", PT: $55) says does not anticipate imminent positive catalysts, but notes pipeline optionality over the next few years (Reporting by Joel Jose in Bengaluru) ((joeljose@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}